Copyright ©The Author(s) 2015.
World J Gastroenterol. May 28, 2015; 21(20): 6117-6126
Published online May 28, 2015. doi: 10.3748/wjg.v21.i20.6117
Table 1 Drugs that can affect the portal hypertension, the effect of which was studied in the experiment
Ref.DrugsExperimental modelEffects
Zhao et al[69]Diammonium glycyrrhizinateCCl4/IPPRLsImproves the bioavailability of NO in portal triads
Di Pascoli et al[70]ResveratrolCCl4Improves vasodilatory response to acetylcholine, decreases TXA2 production, increases endothelial NO and reduces hepatic fibrosis
Yang et al[71]Ursodeoxycholic acidBDLSuppresses hepatic TXA2 production and lipid peroxidation. An increase in antioxidative defence leading to the prevention of hepatic fibrosis
Rodríguez-Vilarrupla et al[72]FenofibrateCCl4Reduces hepatic fibrosis, improves vasodilatory response to acetylcholine, reduces COX-1 expression and TXB2 production, increases NO bioavailability in SEC
Hsieh et al[73]AliskirenBDLAmeliorates the angiotensin II induced intrahepatic vasoconstriction
Luo et al[74]SpironolactoneBDLInhibits hepatic fibrosis, ROCK-2 activity and activates NO/PKG pathway
Gao et al[75]CelecoxibTAAInhibits hepatic fibrosis and angiogenesis. The anti-angiogenesis effect associates with the modulation of VEGF/VEGFR-2
Rosado et al[76]TerutrobanCCl4/BDLIn CCl4-cirrhotic rats decreases hepatic fibrosis, in BDL-rats enhances eNOS-dependent vasodilatation
Wang et al[77]RapamycinBDLAmeliorates intrahepatic inflammation and fibrosis, improves liver function
Laleman et al[78]NitroflurbiprofenFlurbiprofenTAA/IPPRLsDecreases hepatic TXA2 production and increases intrahepatic nitrate/nitrite level
Yang et al[79]Vitamin EBDLAsymmetric dimethylarginine improves hepatic endothelial dysfunction by a vitamin E through an increase of NO bioavailability
Liu et al[80]BlebbistatinIn vitroInhibits the contraction and accelerates migration of HSC
Verbeke et al[81]Obeticholic acidBDLDecreases hepatic vascular resistance by increasing eNOS activity
Steib et al[82]MontelukastTAA/BDLInhibiting the cysteinyl leukotrienes receptors reduces hepatic vascular resistance
Xu et al[83]Salvianolic acid BDMN/In vitroReduces HSCs contractility
Fernandez et al[84]Rapamycin+GleevecPPVLReduces splanchnic neovascularization
Schwabl et al[85]PioglitazoneBDL/PPVLDecreases portosystemic shunting
Fallowfield et al[86]RelaxinCCl4/BDL/In vitroDown-regulates HSC- myofibroblast contractile filament expression and contractile function
Lin et al[87]Bivanib alaninateBDL/ IPPRLs/In vitroSuppresses and ameliorates fibrogenic and angiogenic markers in the serum and liver. Inhibits the TGFβ1-induced HSCs contraction/migration and VEGF-induced SECs angiogenesis